Janux Therapeutics (JANX) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Janux Therapeutics (JANX) has outperformed Vor Biopharma (VOR) over the past year, losing 23.6% versus a loss of 42.7%. Over five years, JANX leads with a -12.4% price change compared with -93.8% for VOR. Vor Biopharma is the larger company by market cap ($1.13 billion vs $1.13 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | VOR |
|---|---|---|
| Share price | $18.50 | $19.13 |
| Market cap | $1.13B | $1.13B |
| 1-day change | +3.24% | +1.86% |
| YTD return | +34.06% | +46.25% |
| 1-year return | -23.55% | -42.72% |
| 5-year return | -12.45% | -93.81% |
| P/E ratio (TTM) | — | 0.11 |
| EPS (TTM) | $-1.64 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.34 | $33.50 |
| 52-week low | $12.12 | $6.50 |
| Distance from 52-week high | -47.65% | -42.90% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +95.89% | +103.87% |
| Average volume | 845.95K | 989.57K |
| Shares outstanding | 61.14M | 59.16M |
| Employees | 113 | 76 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JANX has outperformed VOR by 19.2 percentage points over the past year.
- The two companies sit in different sectors: Janux Therapeutics in Healthcare and Vor Biopharma in Health Care.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Healthcare · Biotechnology · 113 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
JANX vs VOR FAQ
Which is bigger, Janux Therapeutics or Vor Biopharma?
Vor Biopharma (VOR) is larger, with a market capitalization of $1.13B compared with $1.13B for Janux Therapeutics (JANX).
Which stock has performed better over the past year, JANX or VOR?
JANX returned -23.55% over the past 12 months, compared with -42.72% for VOR (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and Vor Biopharma in the same industry?
No. Janux Therapeutics is in the Healthcare sector, while Vor Biopharma is in Health Care.